Novavax awarded department of defense contract for COVID-19 vaccine – Reuters
|Novavax awarded department of defence contract for COVID-19 vaccine, according to Reuters.
Ket notes
- $60 million funding for manufacturing of nvx-cov2373.
- Will work with US-based biologics CDMO to manufacture antigen component of nvx-cov2373 for at least 10 million doses of vaccine.
- Will collaborate with US-based CDMOS to scale up production and manufacture of matrix-m adjuvant component of vaccine.
Market implications
The stock market has rallied as if it were a forgone conclusion that there will be no further spikes in the virus and that a vaccine was imminent. Well, the recent new cases, such as in California, begs to differ.
On Wall Street on Thursday, the S&P 500 index started to reflect how fragile investor's conviction really is. The index was sliding below yesterday's lows and futures struggle to come up for air in Asia.
A Los Angeles Times analysis shows that the number of weekly cases in California continues to rise, exceeding 17,000 last week for the first time in the pandemic. California is one of about 20 states where new cases are increasing over the past five days, according to Johns Hopkins University.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.